ProPhase Labs, Inc. (PRPH)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

ProPhase Labs, Inc. (PRPH) is down 69.3% since the beginning of the year. At $0 per share, PRPH is trading 97.9% below its 52-week high of $7. Investors who bought $1,000 worth of PRPH shares 5 years ago would now be looking at an investment worth $3.

ProPhase Labs, Inc. (PRPH) has returned -69.33% so far this year and -96.33% over the past 12 months. Over the last ten years, PRPH has returned -33.10% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Apr 22, 1997, PRPH's average daily return is +0.06%, while the average monthly return is +0.69%. At this rate, an investment would double in approximately 8.4 years.

Historically, 44% of months were positive and 56% were negative. The best month was Mar 2002 with a return of +130.7%, while the worst month was Dec 2025 at -78.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.

On a daily basis, PRPH closed higher 44% of trading days. The best single day was Aug 17, 2009 with a return of +65.3%, while the worst single day was Nov 8, 2024 at -45.5%.

ProPhase Labs, Inc. has an annualized alpha of 12.66%, beta of 0.30, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since April 23, 1997.

• This stock participated in 93.41% of S&P 500 Index downside but only -14.60% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.30 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PRPH ranks 7 for risk / return — in the bottom 7% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for ProPhase Labs, Inc. (PRPH) and compare them to S&P 500 Index.

ProPhase Labs, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for ProPhase Labs, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ProPhase Labs, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ProPhase Labs, Inc. was 99.95%, occurring on Mar 26, 2026. The portfolio has not yet recovered.

The current ProPhase Labs, Inc. drawdown is 99.91%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ProPhase Labs, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ProPhase Labs, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.